Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
US6410052B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 10, 2000 |
| Grant date | Jun 25, 2002 |
| Priority date | — |
| Expiry date | Aug 10, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5047
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention described herein encompasses a methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group of polyphenols found in green tea, to a mammal in need of such therapy. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). The unique compositions of the invention contain various combinations of the catechins, alone or in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses the varying modes of administration of the therapeutic compounds, including a sustained release formulation which may be used as a therapeutic compound for the treatment of cancer or as a dietary supplement for the prevention of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.